Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide

Derrick Robertson, Crystal Dixon, Angela Aungst, Bradlee McCoy, Natalie Moreo, Lise Casady, Janice Maldonado

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Teriflunomide is an oral disease modifying therapy approved for the treatment of relapsing forms of multiple sclerosis. Teriflunomide’ s pharmacokinetics (PK) contribute to its slow elimination, on average taking 6–8 months, though it can take up to 2 years in some instances. This slow elimination can become problematic in certain clinical situations–such as during pregnancy, when teriflunomide has potential teratogenic effects. In such scenarios, an accelerated elimination procedure (AEP) is recommended. Currently, AEPs with oral cholestyramine or activated charcoal are available but are restricted by adverse effects, limited administration routes, and dosing frequencies. Methods: A single-center, PK interaction study was performed in a total of 14 healthy volunteers, to investigate colestipol hydrochloride (HCl) as an alternative to cholestyramine for the elimination of teriflunomide. Participants received teriflunomide for 14 days, followed by an AEP with colestipol HCl for 15 days. Results and conclusions: The administration of colestipol HCl for 15 days was sufficient to reduce plasma teriflunomide concentrations by greater than 96%. Although colestipol HCl did not completely eliminate teriflunomide with the same effectiveness as cholestyramine, it may offer an alternative method for accelerated elimination of teriflunomide with potentially improved tolerability and more favorable dosing and administration options.

Original languageEnglish (US)
Pages (from-to)1403-1407
Number of pages5
JournalExpert review of clinical pharmacology
Volume10
Issue number12
DOIs
StatePublished - Dec 2 2017
Externally publishedYes

Keywords

  • Teriflunomide
  • accelerated elimination procedure
  • colestipol HCl
  • multiple sclerosis
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide'. Together they form a unique fingerprint.

Cite this